ROBOSENSE
20.9.2019 15:32:12 CEST | Business Wire | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/
True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such as Tesla’s recent cases, greatly improving the security of autonomous driving and ensuring passenger safety.
The RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip) . The RS-LiDAR-M1 transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems.
As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but the RS-LiDAR-M1’s built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
RS-LiDAR-M1’s built-in AI algorithm has went through a large number of extreme and complex environmental tests, such as a variety of road, weather, and traffic conditions, not only in simple situations such as highways, but also with complex challenges such as intersections with Chinese characters during peak commuting hours and dense traffic, in order to ensure that the Smart LiDAR Sensor can provide rich, precise, reliable and redundant information to the self-driving vehicle for driving decision making in real-time under any circumstances.
“The precise information processed and delivered by RS-LiDAR-M1 will help self-driving cars on making meaningful driving decisions based on sufficient redundant information. We are confident that the mass produced RS-LiDAR-M1 is necessary for SAE Level 3 to Level 5 of autonomous driving and ASIL-D advanced safety ”, said Mark, RoboSense COO & Co-founder.
The judges from AutoSens Awards review panel commented that RoboSense Smart LiDAR Sensor technology provides an innovative safety system to the industry, with a fusion of LiDAR sensor hardware and AI perception algorithm software. The judges deemed it a highly valuable system with strong innovation qualities.
The AutoSens Awards are the highlight of the global vehicle perception world. This year in Brussels, Belgium, it invites winners including start-ups, individuals and electronics and automotive giants, representing a thriving industrial ecosystem doing some of the most exciting technology development the world has ever seen. Its review panel consists of world-class experts in the field of automotive and attracts more than 120 participants. RoboSense is the final winner of “Best Automotive Safety System” category. The finalists include world-leading automotive brands as GM, Daimler, and FICOSA and Audi.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving. RoboSense is headquartered in Shenzhen, China with branch offices in the U.S., Germany, Beijing, and Shanghai. Customers include the world’s leading autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers.
For more information please visit: https://www.robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190920005309/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom